Bristol-Myers Squibb Co.

NYSE:BMY   2:15:25 PM EDT
76.93
+1.12 (+1.48%)
Products

U.S. FDA Accepts For Priority Review Bristol Myers Squibb’s Application For Orencia To Prevent Acute Graft Versus Host Disease (Agvhd)

Published: 08/23/2021 12:47 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (agvhd).
Bristol-myers Squibb Co - FDA Assigned an Action Date of December 23, 2021 for Orencia.